Analyst Marie Thibault of BTIG maintained a Buy rating on Edwards Lifesciences, boosting the price target to $103.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Marie Thibault’s rating is based on several promising developments and strategic initiatives by Edwards Lifesciences. The company has shown strong momentum in its Transcatheter Aortic Valve Replacement (TAVR) segment, driven by improved hospital capacity and renewed interest following positive trial results. Looking forward, 2026 is expected to be a year rich with catalysts, including potential updates to national coverage determinations and valvular guidelines, which could significantly enhance patient referrals and treatment pathways.
Furthermore, Edwards Lifesciences is making substantial progress in its transcatheter mitral and tricuspid therapies (TMTT) segment, aiming for significant sales growth by 2030. The anticipated FDA approvals for key devices and the expansion of their implantable heart failure management portfolio highlight a robust pipeline. Additionally, the company’s operating margins are improving, and the strategic initiatives are expected to drive growth, justifying the raised price target from $100 to $103.